Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!

Recruiting

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma - CC-93269-MM-001

Updated: 7 April, 2021   |   ClinicalTrials.gov

Print Friendly Summary

CONSIDERING THIS TRIAL?
Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 1

    Phase

  • Gender(s)

  • 18+

    Age Range

  • 18

    Location(s)

  • Recruiting

Treatment Options

Study Arms
ASSIGNED INTERVENTION
Experimental: Administration of CC-93269
Drug: CC-93269

Key Eligibility Criteria

Inclusion Criteria: Subjects must satisfy the following criteria to be enrolled in the study: 1. Subject must understand and voluntarily sign an informed consent form (ICF) prior to any study-related assessments/procedures being conducted. 2. Subject (male or female) is ≥ 18 years of age the time of signing the ICF. 3. Subject has non-secretory multiple myeloma, plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) syndrome, or amyloidosis. 4. Subjects must have measurable disease (as determined by the central lab). 5. Subject consents to hospitalization for monitoring and collection of study peripheral blood samples. 6. Subject consents to serial bone marrow aspirations and/or biopsies during Screening, study treatment and at the end of treatment. 7. Subject has an Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1. 8. Subjects must have adequate hematologic, liver, renal, and coagulation function as assessed by laboratory tests. 9. Females and males must practice true abstinence or agree to contraceptive methods throughout the study, and during the safety follow-up period. Exclusion Criteria: The presence of any of the following will exclude a subject from enrollment: 1. Subject has received prior therapy directed at B cell maturation antigen (BCMA). 2. Subject has symptomatic central nervous system involvement of multiple myeloma. 3. Subject has non-secretory multiple myeloma, plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or amyloidosis. 4. Subject is on chronic systemic immunosuppressive therapy or corticosteroids. 5. Subjects with clinically significant cardiac disease. 6. Subject had a prior autologous stem cell transplant ≤ 3 month prior to starting CC-93269. 7. Subject had a prior allogeneic stem cell transplant ≤ 12 month prior to starting CC-93269. 8. Subject had a prior systemic cancer-directed treatments or investigational modalities ≤ 5 half-lives or 4 weeks prior to starting CC-93269, whichever is shorter. Subjects must have recovered from any clinically significant non-hematologic toxicities (ie, to Grade ≤1) of prior systemic anti-cancer directed treatments unless otherwise specified 9. Subject had major surgery ≤ 2 weeks prior to starting CC-93269. 10. Subject is a pregnant or lactating female. 11. Subject has known history or serologic evidence of human immunodeficiency virus (HIV) infection. 12. Subject has known history, virologic or serological evidence of hepatitis B or C virus (HBV/HCV) infection. Subjects who had HCV but have received an antiviral treatment and show no detectable HCV viral RNA for 6 months are eligible 13. Subject has a history of a venous thromboembolic event (VTE) within 6 months prior to study entry (eg, deep-vein thrombosis or pulmonary embolism). Subjects with distant history of VTE (ie, occurring > 6 months prior to study entry) who require ongoing treatment with chronic, therapeutic dosing of anti-coagulants (eg, warfarin, low molecular weight heparin, Factor Xa inhibitors) are eligible for study entry. 14. Subject has a history of concurrent second cancers requiring active, ongoing systemic treatment. 15. Subject has a history or presence of clinically relevant central nervous system (CNS) pathology. 16. Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study. 17. Subject has any condition (eg, active or uncontrolled infection) including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study. . 18. Subject has any condition that confounds the ability to interpret data from the study. 19. Subject has inadequate pulmonary function. 20. Subject has active, uncontrolled, or suspected infection. 21. Subject has pulmonary, cardiac, or hepatic involvement of extramedullary multiple myeloma. 22. Subjects with a history of severe allergic or anaphylactic reactions or hypersensitivity to excipients in the investigational product. 23. Recent SARS-CoV-2 vaccine as specified in the protocol.

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com